12 Most Oversold Healthcare Stocks to Buy Now

Page 9 of 12

4. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Year Perf: -30.99%

Analyst Upside: 93.22%

Number of Hedge Fund Holders: 27

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) develops medicines that treat intractable diseases by silencing the genes that cause them. Employing a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, its portfolio of therapies triggers the RNA interference (RNAi) mechanism and induces rapid, durable, and deep knockdown of target genes. The company specializes in various therapeutic domains, including liver, muscle, cardiometabolic, and central nervous system. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has around 14 clinical-stage investigational medicines, of which nine are wholly owned, and five are partnered.

The company recently closed a potentially transformational licensing and collaboration agreement with Sarepta Therapeutics and submitted its first NDA for investigational plozasiran, a first-in-class investigational RNA interference (RNAi) therapeutic, which was accepted for filing by the FDA. Management says that the company is funded into 2028 and well-positioned for growth in 2025 and beyond, with plans for an independent commercial launch in 2025 and the potential for multiple partner launches over the coming few years.

Plozasiran, obesity, and the central nervous system are key value drivers fueling growth from its internal development activities in the near term. Arrowhead Pharmaceuticals, Inc.’s (NASDAQ:ARWR) obesity and CNS programs are entering early clinical studies, and the company sees emerging high-value potential in them.

Page 9 of 12